Diaceutics Appoints Yvanka Gilliam as Vice President of Operations, Asia Pacific
April 12 2021 - 10:05AM
Business Wire
- Yvanka Gilliam brings a wealth of industry experience to the
company, having worked in pharma for more than 20 years
- Prior to Diaceutics, she had roles in Kantar Health, IQVIA Asia
Pacific and AstraZeneca
- Yvanka will be responsible for managing business development
and operations in the APAC region
- Yvanka’s role will also include identifying innovative and
creative services and solutions to help leverage the Diaceutics’
DXRX platform
Diaceutics PLC, (AIM: DXRX), today announces the appointment of
Yvanka Gilliam as Vice President of Operations, Asia Pacific
(APAC).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210412005504/en/
Newly-appointed Diaceutics VP of
Operations, APAC, Yvanka Gilliam. (Photo: Business Wire)
In her new role, Yvanka will be responsible for managing
business development and operations within the APAC region with a
core focus on establishing key collaborations and strategic
partnerships to drive growth and revenue. Her role will also
include identifying innovative and creative services and solutions
to help leverage the company’s platform, DXRX, and increase the
offering.
Yvanka has a strong track record managing the delivery of
real-world insights for evaluation by regulators, payers and
clinicians. Prior to joining Diaceutics, Yvanka worked with Kantar
Health as a Senior Client Partner, Real World Evidence, where she
developed and implemented global business planning strategies and
conducted high-quality research. In recent years, Yvanka has also
worked with IQVIA Asia Pacific in the Real World Insights Division
and as a Senior Medical Science Liaison at AstraZeneca
Pharmaceutical Corporation.
Yvanka holds a doctorate degree in Pharmacy from The University
of Michigan College of Pharmacy in Ann Arbor, a bachelor’s degree
in Biology and Chemistry from Grambling University in Louisiana and
an MBA in International Business from Rutgers University Singapore.
Yvanka’s work has been published in the Annals of Oncology and the
Journal of Clinical Oncology – an American Society of Clinical
Oncology (ASCO) Journal.
Peter Keeling, Chief Executive Officer of Diaceutics,
said: “Yvanka’s appointment will strengthen Diaceutics’
credentials as the market leader in the development and
commercialization of precision medicine diagnostics. As her 20-plus
year career in pharma has been focused primarily on the Research
and Development of innovative oncology compounds, Yvanka is firmly
aligned with Diaceutics’ goal to bridge the gap between diagnostics
and therapeutic decision-making in order to improve testing
outcomes for patients and enable better access to the right drug at
the right time.”
Yvanka Gilliam, Diaceutics VP of Operations, APAC, said:
“I’m delighted to join Diaceutics, a company that I have long
admired for their unwavering commitment to drive better testing and
better treatment for patients. I look forward to broadening
Diaceutics’ influence in the APAC region and working alongside a
team of driven and talented individuals. I’m particularly excited
to come on board as the company’s DXRX – The Diagnostic Network®
platform continues to gain traction within the industry, as we help
get every patient the treatment they deserve.”
-ENDS-
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX – the world’s first
diagnostic network for precision medicine. Diaceutics has worked on
every precision medicine brought to market and provides services to
36 of the world’s leading pharmaceutical companies. We have built
the world’s largest repository of diagnostic testing data with a
growing network of 2500 labs in 51 countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210412005504/en/
Rebecca Hughes Comit Communications & Marketing Ltd. M: +353
85 822 2055 E: rebecca@comit.ie
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024